Jonathan A. Ledermann, MD, and Ursula A. Matulonis, MD, on Olaparib Maintenance Monotherapy for Ovarian Cancer
2016 ASCO Annual MeetingJonathan A. Ledermann, MD, of Cancer Research UK and University College London Cancer Trials Centre, and Ursula A. Matulonis, MD, of the Dana-Farber Cancer Institute, discuss findings on overall survival in patients with platinum-sensitive relapsed serous ovarian cancer receiving olaparib maintenance monotherapy (Abstract 5501).
Related Videos
Paul E. Goss, MD, PhD, on Postmenopausal Early-Stage Breast Cancer: Extending Letrozole Treatment
Paul E. Goss, MD, PhD, of Massachusetts General Hospital Cancer Center and Harvard Medical School, discusses disease-free survival results from a study extending adjuvant letrozole fo...
Arjun Vasant Balar, MD, on Urothelial Carcinoma: Analysis of the IMvigor210 Cohort 1
Arjun Vasant Balar, MD, of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses findings on atezolizumab as first-line therapy in cisplatin-ineligible locally advance...
Luis G. Paz-Ares, MD, PhD, on NSCLC: Results from the SQUIRE Trial (Spanish Language Version)
Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses in Spanish study findings on adding necitumumab to gemcitabine and cisplatin chemotherapy in the firs...
Patricia J. Goldsmith on Patient Access and Engagement: Results of the CancerCare Report
Patricia J. Goldsmith, Chief Executive Officer of CancerCare, which provides free, professional support services to anyone affected by cancer, discusses findings from six dis...
Julie Lemieux, MD, on Letrozole in Postmenopausal Early-Stage Breast Cancer: Patient-Reported Outcomes (French Language)
Julie Lemieux, MD, of Centre Hospitalier Universitaire de Québec, discusses in French patient-reported outcomes from a study extending adjuvant letrozole for 5 years afte...
